Biopharma Shakti Scheme

1. At a Glance

Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology and Innovation; central sector scheme to build a globally competitive biologics and biosimilars ecosystem in India [S1][S2].
Outlay ₹10,000 crore over 5 years; objective: position India as a global biopharma manufacturing & innovation hub while keeping healthcare affordable [S1][S2].
Implemented by Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (with CDSCO, ICMR, NIPER as delivery arms) [S1].
High UPSC relevance: cuts across GS-II (health governance, regulators) and GS-III (S&T, industry, IPR, Make-in-India).

Announced in Union Budget 2026-27 by FM as one of seven strategic/frontier manufacturing thrusts; formally notified by Department of Pharmaceuticals [S2][S3][S4].
PIB release dated 27 March 2026 consolidated the scheme architecture (CDSCO cadre, 1,000-site clinical trial network) [S1].

Rationale: India is "pharmacy of the world" in small-molecule generics, but lags in biologics/biosimilars, gene therapy and fermentation-based bulk drugs [S2][S4].
Predecessor / parallel schemes: PLI for Pharmaceuticals, PLI for Bulk Drugs/APIs, Bulk Drug Parks scheme, National Biopharma Mission (NBM) under DBT-BIRAC [S5][S2].
Budget 2026-27 announcement (Feb 2026) → scheme architecture detailing in Mar 2026 [S3][S1].

Full form: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S2].
Nodal ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
Outlay: ₹10,000 crore [S1][S2]; Duration: 5 years [S1].
Key pillars [S2][S4]: 1. Biopharma Discovery Grant Fund + Discovery & Development Equity Fund. 2. Biopharma-focused NIPER Network + National Biopharma R&D Network. 3. India Clinical Trial Sites Network — 1,000 nationally accredited sites (under ICMR linkage) [S1][S4]. 4. Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive.
Regulator reform: dedicated Scientific Review Cadre in CDSCO with specialist posts for advanced fields incl. gene therapy [S1][S4].
NIPER expansion: 3 new NIPERs + upgradation of 7 existing NIPERs [S2][S4].
Strategic target: capture ~5% of global biopharmaceutical market [S2].

Economic
Anchors a higher-value pharma export basket (biologics command higher margins than generics) [S2].
Equity + grant funds de-risk private R&D capex in fermentation, mAbs, cell & gene therapies [S2][S4].
Scientific / Technological
Builds domestic capability in biosimilars, gene therapy, recombinant proteins; addresses CDSCO's technical bandwidth gap via specialist cadre [S1][S4].
1,000-site clinical trial network plugs a long-standing weak link in translational pipelines [S1].
Social
Affordable access to high-cost biologics (oncology, autoimmune, rare-disease) is the explicit equity goal [S1].
Geopolitical / Strategic
Listed among 7 strategic & frontier manufacturing sectors in Budget 2026-27 — pharma self-reliance is a hedge against API/biologic import dependence on China [S3][S4].
Administrative / Governance
Convergence model: DoP (scheme owner), CDSCO (regulation), ICMR (trial sites), NIPERs (talent), BIRAC/DBT ecosystem linkages [S1][S2].

Feb 2026: Biopharma SHAKTI announced in Union Budget 2026-27 by FM [S3].
Feb 2026: Minister Dr. Jitendra Singh frames the scheme as catalysing India's role in the "next industrial revolution" and a global biomanufacturing hub [S3].
Mar 2026 (27 Mar): Department of Pharmaceuticals lays out scheme architecture — ₹10,000 cr outlay, CDSCO Scientific Review Cadre, 1,000 accredited trial sites [S1].

Biopharma SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S2].
Outlay: ₹10,000 crore over 5 years [S1].
Nodal: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (NOT Ministry of Health, NOT DBT) [S1].
Announced in Union Budget 2026-27 [S3].
Targets a 1,000-site nationally accredited clinical trial network [S1].
Creates a Scientific Review Cadre inside CDSCO for advanced fields incl. gene therapy [S1][S4].
Includes 3 new NIPERs + upgradation of 7 existing NIPERs [S2][S4].
Strategic aim: ~5% of global biopharma market share [S2].
Has a Fermentation-based Bulk Drugs & Building Blocks manufacturing incentive [S2].
One of 7 strategic & frontier manufacturing sectors in Budget 2026-27 [S3].
Focus area = biologics & biosimilars (not small-molecule generics) [S1].
Includes both a Discovery Grant Fund and a Discovery & Development Equity Fund [S2].

GS-III — Indian Economy (Industrial Policy, Make-in-India), Science & Technology (Biotech, Indigenisation of Technology), Pharma sector.
GS-II — Government policies for the health sector; statutory/regulatory bodies (CDSCO, ICMR).
Probable question stems: 1. "Discuss how the Biopharma SHAKTI scheme seeks to transition India from a generics powerhouse to a biologics innovation hub. What are the key implementation challenges?" 2. "Strengthening CDSCO is central to India's biopharma ambitions. Examine in the context of the Biopharma SHAKTI scheme." 3. "Evaluate the role of clinical trial infrastructure and NIPER network in achieving the goals of Biopharma SHAKTI."

PLI Scheme for Pharmaceuticals & Bulk Drugs (APIs) — complementary supply-side push [S6].
National Biopharma Mission (NBM) / BIRAC — DBT's earlier biopharma initiative.
CDSCO & Drugs and Cosmetics Act, 1940 / New Drugs & Clinical Trials Rules, 2019 — regulatory backbone.
NIPERs — talent pipeline for the scheme.
Bulk Drug Parks Scheme — manufacturing infrastructure complement.
National Policy on R&D and Innovation in Pharma-MedTech (PRIP) — adjacent innovation scheme.
Jan Aushadhi (PMBJP) — affordability angle.
India's Genome India Project / Anusandhan NRF — upstream science base.

Ministry confusion: scheme sits under Department of Pharmaceuticals (Min. of Chemicals & Fertilizers), NOT Ministry of Health & Family Welfare, NOT DBT [S1].
Acronym trap: SHAKTI here ≠ SHAKTI in coal/power sector (Scheme for Harnessing & Allocating Koyala Transparently in India). Same acronym, totally different scheme.
Outlay confusion: scheme outlay is ₹10,000 cr; a separate PIB note references "₹13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks" — that figure is combined, not scheme-only [S5][S1].
Focus area: it targets biologics/biosimilars, not small-molecule generics or medical devices.
Clinical trial network number: 1,000 sites, accredited (not 100, not 10,000) [S1].

[S1] Biopharma Shakti Scheme — PIB, Dept. of Pharmaceuticals, 27 Mar 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2246063 — (tier 1)
[S2] Transforming India into a Global Biopharma Hub — Budget 2026-27 Series, PIB — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202622776701.pdf — (tier 1)
[S3] Budget 2026-27 announcement of "Biopharma Shakti" — Dr. Jitendra Singh, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778 — (tier 1)
[S4] BIOPHARMA SHAKTI proposed in Union Budget 2026-27 — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221443 — (tier 1)
[S5] Provision of Rs 13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235160 — (tier 1)
[S6] Extension of PLI Scheme to API — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2239580 — (tier 1)